4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-26-000028
CHIEF EXECUTIVE OFFICER sold 10,501 shares at an average $60.77 ($638,104)
- CHIEF EXECUTIVE OFFICER acquired 18,750 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-16 | Option exercise | +18,750 | 114,873 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-16 | Sale | −2,140 | $59.75 | $127,874 | 112,733 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-16 | Sale | −5,932 | $60.83 | $360,838 | 106,801 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-16 | Sale | −2,429 | $61.50 | $149,392 | 104,372 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-06-16 | Option exercise · Restricted Stock Unit | −18,750 | 56,250 | D | ||
| Open-market sales · 10,501 sh · avg $60.77 · $638,104 | |||||||
Loading xslF345X06/form4-06182026_080658.xml…